iMTA

Cost Effectiveness in Multiple Sclerosis

Multiple Sclerosis treatment is improving, but do we capture these effects?

For over 25 years, the institute for Medical Technology Assessment (iMTA) has played a key role in HTA research.

iMTA developed novel ways to identify health outcomes suitable for economic evaluations (‘utilities’).

Key achievements in the field of Multiple Sclerosis

Costing study

iMTA performed a costing study for intrathecal baclofen therapy against spasms, also occurring in multiple sclerosis. The pump was fitted in a home based situation to avoid that patients have to return to the hospital.

more info →

Preference measurement DCE / TTO

iMTA developed the condition specific MSIS-PBM, a preference based instrument based on the Multiple Sclerosis Impact Scale 29. Using the Time Trade-off method in about 400 group interviews in The Netherlands, a selection of items (selected using Rasch-analysis and expert opinion) of the MSIS-29 was weighted. The resulting instrument is more sensitive than EQ5D for minor impairments and better discriminates between patients with EDSS score 3,4 and 5 than EQ5D. Utilities can be calculated from the MSIS-29 directly.